National prevalence of gout derived from administrative health data in Aotearoa New Zealand

Winnard, Doone; Wright, Clinton S.; Taylor, William J.; Jackson, Graham S.; Karu, Leanne Te; Gow, Peter; Arroll, Bruce; Thornley, Simon; Gribben, Barry; Dalbeth, Nicola

doi:10.1093/rheumatology/ker361

Cited by 178 publications

(155 citation statements)

References 28 publications

Supporting

Mentioning

138

Contrasting

Unclassified

Order By: Relevance

“…One of the most extensive epidemiological studies was undertaken by Winnard et al, who used national health data sets to sample more than 4 million of the Aoteoroa New Zealand (NZ) population; 7 this group identified a prevalence of gout of 3.75%. Both Winnard and Stamp et al also found a higher prevalence or hyperuricaemia in the NZ Maori population compared with the Non-Maori population.…”

Section: Introductionmentioning

confidence: 99%

“…Both Winnard and Stamp et al also found a higher prevalence or hyperuricaemia in the NZ Maori population compared with the Non-Maori population. 7,8 In the general US population, the prevalence of medical record diagnosed gout was 3.9% and the prevalence of hyperuricaemia was 21.4%. 9 In the UK and Europe the prevalence of gout is considerably lower; a retrospective analysis of general practitioner records from 2000-2005 revealed a gout prevalence of only 1.4%.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence and associations of gout and hyperuricaemia: results from an Australian population‐based study

Ting

Gill

Keen

et al. 2016

Internal Medicine Journal

View full text Add to dashboard Cite

ABSTRACT:Background:Despite gout and hyperuricaemia being major co-morbid health issues worldwide, there is a large epidemiological gap regarding their impact in the Australian community. Aims:To determine the prevalence and associations of self-reported medically diagnosed gout, and hyperuricaemia, in an Australian population-based cohort. Methods:The North West Adelaide Health Study (NWAHS) is a longitudinal cohort study consisting of three stages of data collection. Each stage comprised a self-complete questionnaire, clinic assessment and Computer Assisted Telephone Interview (CATI). In Stage 3 (2008-2010) participants were asked if a doctor had ever diagnosed them with gout. Additional data included demographics, co-morbidities, laboratory data and SF-36. Participants were defined as having gout if they had self-reported medically diagnosed gout or were taking any gout specific medication (allopurinol, colchicine, probenecid). Hyperuricaemia was defined as a serum uric acid level >0.42mmol/L in men and >0.34mmol/L in women. Results:The overall prevalence of gout was 5.2%. Males were significantly more likely to have gout than females (8.5% vs 2.1%, p<0.001). The overall prevalence of hyperuricaemia was 16.6%, with being male again identified as a significant risk factor (17.8% vs 15.4%, p<0.01). Both gout and hyperuricaemia were associated with male sex, body mass index, and renal disease, after 2 multivariable adjustment. There was no significant difference reported in quality of life scores in gout participants, compared to unaffected individuals. Conclusion:In the South Australian population the prevalence of gout and hyperuricaemia is high. This study emphasises the need for optimal diagnosis and management of gout in Australia.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prevalence and associations of gout and hyperuricaemia: results from an Australian population‐based study

Ting

Gill

Keen

et al. 2016

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

“…Clinicians are aware of the suffering of gout and of the need to provide effective education about lifestyle and medications. [14][15][16] We found interviewees were frustrated that gout was treated mainly as an acute condition rather than addressing the barriers to initiating preventive action and treating gout as a chronic disease. They felt there was inadequate time for patient education.…”

Section: Discussionmentioning

confidence: 99%

A qualitative study to explore health professionals’ experience of treating gout: understanding perceived barriers to effective gout management

Humphrey

Hulme²,

Dalbeth

et al. 2016

J Prim Health Care

View full text Add to dashboard Cite

IntroductIon: The management of gout is challenging and mainly occurs in primary care. This study aims to explore the experience of treating gout among primary care clinicians and understand the perceived barriers to effective therapy.Methods: Fourteen health professionals from primary care practices in South Auckland were recruited. Each participated in a semi-structured interview exploring their experience of treating and managing gout patients were analysed thematically.FIndIngs: Participants described the large burden of gout in their communities and the importance of the clinician-patient relationship in gout management. Four themes summarise the perceived barriers to effective urate lowering therapy (ULT); unique gout factors, eg its intermittent nature and potential for stigmatisation; systemic barriers to optimal treatment, or barriers that emerge from working within a certain organisation; uncertainty about ownership, or who should carry responsibility for overcoming barriers to optimal treatment; and cultural barriers to optimal treatment. conclusIon: Clinicians in primary practice perceive gout management to be mainly acute rather than preventive care. Patients may be stigmatised and management difficult particularly when diet is emphasised over ULT. Practice nurses are a group potentially available and willing to assist in educating patients. These findings may be helpful in planning for and improving healthcare in gout.

show abstract

“…1,2 In 2009, a NZ study reported a nationwide prevalence of gout of 2.89% but the rate among Māori and Pacific men was at least ORIGINAL SCIENTIFIC PAPER ORIGINAL RESEARCh: CLINICAL double the national average (6.06% and 7.63%, respectively). 3 The greater prevalence among certain ethnic groups is due to genetic variation in uric acid excretion combined with factors such as lower socioeconomic status, barriers to healthcare, lower health literacy, medication non-adherence and risk averseness to treatment. 3,4 Despite longstanding, clinically useful pharmacotherapeutic agents like colchicine and allopurinol, gout remains poorly managed.…”

Section: Introductionmentioning

confidence: 99%

“…3 The greater prevalence among certain ethnic groups is due to genetic variation in uric acid excretion combined with factors such as lower socioeconomic status, barriers to healthcare, lower health literacy, medication non-adherence and risk averseness to treatment. 3,4 Despite longstanding, clinically useful pharmacotherapeutic agents like colchicine and allopurinol, gout remains poorly managed. 5 Patient views, and those of the wider community, that gout is a minor condition caused by overindulgence of food or drink and only requires medication during the acute phase, has normalized the condition and allowed it to be tolerated.…”

Section: Introductionmentioning

confidence: 99%

Patient awareness, knowledge and use of colchicine: an exploratory qualitative study in the Counties Manukau region, Auckland, New Zealand

et al. 2016

View full text Add to dashboard Cite

IntroductIon: Treatment of gout, specifically with colchicine, varies globally. Colchicine can be fatal due to its narrow therapeutic index and potential for interactions. In New Zealand, cases of intentional and unintentional colchicine overdose have been documented. AIms:To explore patients' knowledge on the use of gout medicines, and in particular their awareness of the maximum dose of colchicine, the dangers of colchicine overdose, and their opinions on restricting colchicine dispensing. The study also investigates where patients receive gout information.methods: Thirty people with gout presenting to their regular gout clinic in Auckland currently or previously taking colchicine were invited to participate in a 30-min semi-structured interview. Data were analysed using a general inductive thematic approach.FIndIngs: Overall, participants had a lack of knowledge regarding colchicine and used variable doses during an acute gout attack. Participants were unsure of the maximum dose of colchicine and several took more than prescribed. The prophylactic use of colchicine and allopurinol varied from 3 weeks to 15 years. Mixed views were reported on restricting colchicine supply. Most participants received gout information from their general practitioner (GP).conclusIon: Poor understanding of colchicine contributed to inappropriate use and highlights the need for targeted patient education. Considerable inter-patient variability exists in the use of colchicine for acute gout, suggesting the efficacy of low dose regimens be explored. The length of adjunctive colchicine use, as part of a prophylaxis regimen, needs to be regularly reviewed and tailored to each patient. Further research is required on limiting the amount of colchicine dispensed.

show abstract

National prevalence of gout derived from administrative health data in Aotearoa New Zealand

Cited by 178 publications

References 28 publications

Prevalence and associations of gout and hyperuricaemia: results from an Australian population‐based study

Prevalence and associations of gout and hyperuricaemia: results from an Australian population‐based study

A qualitative study to explore health professionals’ experience of treating gout: understanding perceived barriers to effective gout management

Patient awareness, knowledge and use of colchicine: an exploratory qualitative study in the Counties Manukau region, Auckland, New Zealand

Contact Info

Product

Resources

About